206-838-5110 ext. 102 general@etubics.com

etubics join

SEATTLE – (July 20, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, has added Dr. Thomas Caskey to its Board of Directors and Drs. / Jerome Zeldis, Slobodan Paessler to its Scientific Advisory Board. The company is currently in development of the Etubics Platform with the National Cancer Institute, which will employ novel immunotherapeutic cancer treatments in clinical trials.

Dr. Caskey is board certified in internal medicine, medical genetics, and molecular genetics. He is currently a professor of molecular and human genetics at Baylor School of Medicine in Houston, Texas, as well as the founder of its Medical Genetics Laboratories. Previously, Caskey was the director and CEO of the Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center in Houston. Past positions include senior vice president of Human Genetics and Vaccines Discovery at Merck Research Laboratories and president of the Merck Genome Research Institute as well as past president of the Human Genome Organization, the American Society of Human Genetics and the Academy of Medicine, Engineering and Science of Texas. Caskey received his undergraduate degree from the University of South Carolina, and his doctorate of medicine from Duke University.

Dr. Zeldis is currently the chief executive officer of Celgene Global Health and chief medical officer of Celgene Corporation in Summit, New Jersey. In his tenure with Celgene, Zeldis has helped grow the company into one of the world’s largest pharmaceutical firms, with revenues in 2012 exceeding $5 billion. He has also worked at Sandoz Research Institute and the Janssen Research Institute, in both clinical research and medical development. Zeldis has served on several boards of directors, including PTC Therapeutics, BioSig Technologies, and Alliqua Biomedical. He has both bachelor’s and masters of science degree from Brown University; master of philosophy from Yale University, and both an M.D. and Ph.D. from the Yale University School of Medicine.

Dr. Paessler specializes in viral pathogenesis and vaccine development and is currently a professor in the Department of Pathology and director of Galveston National Laboratory Preclinical Studies Core, both at University of Texas Medical Branch. He also serves as the director of Animal Biosafety Level 3 for the Institute of Human Infections and Immunity and is a member of the Center for Biodefense & Emerging Infectious Diseases. Paessler has a bachelor’s degree in veterinary sciences from the Agriculture and Veterinary School in Osijek, Croatia; a doctorate of Veterinary Medicine (DVM) from Ludwig-Maximilian University in Munich, Germany; and a Ph.D. in experimental pathology from the University of Texas Medical Branch, School of Biomedical Sciences in Galveston, Texas.

About Etubics Corporation
Etubics Corporation, based in Seattle, Wash., is a third generation clinical stage bio-pharmaceutical company developing a proprietary gene delivery platform technology consisting of a genetically engineered adenovirus vector delivery system and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Phase 1 and 2 clinical trials to date show that the Etubics Platform overcomes challenges associated with all other viruses including prior generation adenoviruses. The Company’s gene delivery platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of cancers, infectious diseases and other chronic illnesses associated with genetic abortions.

Forward look statements:
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.

Media Contacts           

Kimberly French / Jason Hamilton

Richmond Public Relations / 206-682-6979

Kimberlyf@richmondpr.comjasonh@richmondpr.com